Ipamorelin Dosage: What the Studies Administered

The short version

There is no established human dose of ipamorelin, because ipamorelin is not an approved medicine ^[3]. What exists are the specific amounts that specific studies gave to specific subjects — and those are reported here as history, not instruction. In the one human pharmacokinetic study, volunteers received single intravenous infusions; the drug cleared with a half-life of about 2 hours ^[2]. In the failed surgery trial, patients got 0.03 mg/kg into a vein twice a day ^[3]. Animal studies used a range of doses by injection ^[4][5]. None of these is a recommendation, and this page deliberately gives no "how much to take" guidance — that would be both unsafe and outside what the evidence supports. The numbers are here so you can see exactly what was tested.

Doses recorded in the studies

The doses below are administered doses from published studies, given in third person. They are not converted into human protocols.

• Human pharmacokinetic study: single intravenous infusions of 4.21–140.45 nmol/kg over 15 minutes ^[2].
• Human Phase 2 ileus trial: 0.03 mg/kg intravenously twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, and 450 µg/day subcutaneously, divided three times daily, for 15 days ^[4].
• Ferret cachexia study (2024): 1–3 mg/kg intraperitoneally ^[5].

A recurring theme across these is that the human work used intravenous dosing under study conditions, while the dominant route in real-world research use — subcutaneous self-administration — has no published human pharmacokinetic or safety characterization at all ^[3].

Half-life and clearance

In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours after intravenous dosing, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg ^[2]. The growth-hormone response is a single discrete pulse, peaking about 40 minutes after the dose and then subsiding ^[2].

The short half-life is the pharmacological reason ipamorelin is described as producing a pulse rather than a sustained elevation. It is also why the molecule, in research settings, was studied with repeat dosing rather than a single daily exposure — though, again, no human dosing schedule is endorsed here ^[2].

Routes studied

The routes appearing in the ipamorelin literature are all parenteral for the parent peptide. Intravenous dosing carries the human pharmacokinetic and clinical-trial data ^[2][3]. Subcutaneous dosing carries the rodent bone and body-composition studies and is the dominant route in community use ^[4]. Intraperitoneal injection appears in rodent and ferret efficacy work ^[5]. Intranasal delivery shows roughly 20% bioavailability in a rodent note. Oral dosing applies only to engineered ipamorelin-derived analogs, not to ipamorelin itself, which is not orally bioavailable — covered in detail on the ipamorelin oral page.

How much cjc-1295 ipamorelin should i take

How much cjc-1295 ipamorelin should I take? This site cannot and does not answer that. There is no approved or trial-validated human dose for ipamorelin or for the CJC-1295 plus ipamorelin combination ^[3]. The community subcutaneous "stack" protocols circulating online have no peer-reviewed human dosing basis and must be treated as anecdotal, not as recommendations ^[3]. A 2020 andrology review discusses the gap between such marketed use and any approved indication for this class ^[10].

How to reconstitute cjc-1295 ipamorelin 5mg

How to reconstitute cjc-1295 ipamorelin 5mg? Ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and reconstituted with bacteriostatic water for research handling ^[2]. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and this site gives no volumes, concentrations, or dosing math for human use.